The medical use of Olaparib Tablets has brought about major changes to BRCA-related advanced ovarian and breast cancer treatments in Nigeria's healthcare system. As a strong PARP inhibitor, olaparib prevents the function of enzymes that repair broken cellular DNA. The process of genomic instability, which occurs when cancer cells lose their ability to repair damage, leads to selective cell death, which resembles the destruction of a building after its last supporting element has been removed. Clinical Indications for Olaparib Olaparib is specifically indicated for: Maintenance Treatment: Monotherapy for germline BRCA-mutated advanced ovarian cancer. Nigeria Regulatory Compliance: Adherence to NAFDAC and SAHPRA safety protocols for olaparib. Safety and Global Distribution Integrity Maintaining a secure supply chain is a risk-management necessity for B2B entities. For pharmaceutical wholesale requirements across South Africa, Ghana, and Cameroon, sourcing must prioritize integrity.